The first line of treatment for schizophrenia is psychotropic medication. Most people with schizophrenia also require adjunctive treatments to enhance the effectiveness of medications, and help manage ...

Cobenfy (xanomeline/trospium chloride; formerly KarXT) was approved for schizophrenia in adults by the Food and Drug Administration in late September. The drug has a novel mechanism of action ...

Since a schizophrenia drug, the first in decades with an innovative mechanism of action, gained US regulatory approval in September, some researchers have proclaimed a new era for psychiatric ...

For Boehringer, the deal adds to a broad pipeline in schizophrenia that spans both pharmacological and digital therapeutic (DTx) products. Leading the charge for new drug therapies is iclepertin ...

Bristol-Myers Squibb's $14 billion bet on buying Karuna Therapeutics looks set to pay off after it got FDA approval for the schizophrenia drug at the heart of the deal. The US regulator has ...

Nov 5 (Reuters) - Intra-Cellular Therapies (ITCI.O), opens new tab said on Tuesday its drug to prevent relapses in schizophrenia patients met the main goal of a late-stage trial. Schizophrenia ...

Antipsychotic medications are prescription pharmaceuticals used to treat conditions that involve psychosis, a group of symptoms that affects the ability to tell what is real and what is not accurate.

Nov 11 (Reuters) - AbbVie (ABBV.N), opens new tab shares fell over 12% on Monday after an experimental schizophrenia drug the company acquired last year failed two mid-stage studies, widening ...

AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said. On Monday AbbVie (ABBV) said that its Phase 2 trial ...

AbbVie said Monday that its experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company, which got the drug through its recent $9 billion ...

(Bloomberg) -- AbbVie Inc. shares fell the most in more than four years after two mid-stage trials of its drug to treat schizophrenia failed to meet their primary goal, a blow to the company’s $ ...